A wave of expiries will hit high-value assets, including Keytruda, Eliquis, Ibrance, and Trulicity, amplifying revenue vulnerability for companies with concentrated blockbuster dependence.

Debates over drug patents are increasingly driven by slogans rather than substance. Claims of “evergreening,” “patent thickets,” and abusive exclusivity are routinely invoked to justify policy ...

As famously explained by Clayton Christensen in The Innovator’s Dilemma, innovation disrupts an industry first by offering a simple and affordable alternative, with initially inferior quality and then ...